In CLARITY AD, lecanemab slowed decline on CDR-Sum of Boxes by 0.45 points over 18 months (95% CI −0.67 to −0.23; P<0.001), with amyloid-related imaging abnormalities involving edema or effusion in 12.6% of 1,795 participants. Those events are not evenly distributed across genotypes, and ε4 homozygotes carry the highest risk — which is why APOE genotyping now forms part of pre-treatment risk assessment. This guide covers registry search, the four criteria that disqualify most applicants, and what to ask a coordinator before consenting.